Cancer Research Meeting Calendar  Jordan
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 46, 2021-2026, April 1, 1986]
© 1986 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rowe, T. C.
Right arrow Articles by Liu, L. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rowe, T. C.
Right arrow Articles by Liu, L. F.

DNA Damage by Antitumor Acridines Mediated by Mammalian DNA Topoisomerase II1

Thomas C. Rowe2, Grace L. Chen, Yaw-Huei Hsiang and Leroy F. Liu3

Department of Biological Chemistry, Johns Hopkins Medical School, Baltimore, Maryland 21205

Antitumor drugs from many chemical classes have been shown to induce protein-linked DNA breaks in cultured mammalian cells and in vitro in the presence of purified mammalian DNA topoisomerase II. The possibility that mammalian DNA topoisomerase II is an intracellular target which mediates drug-induced DNA breaks is supported by the following studies using 4'-(9-acridinylamino)methane-sulfon-m-anisidide (m-AMSA): (a) a single m-AMSA-dependent DNA cleavage activity copurified with calf thymus DNA topoisomerase II activity at all chromatographic steps of the enzyme purification; (b) m-AMSA-induced DNA cleavage by this purified activity resulted in the covalent attachment of protein to the 5'-ends of the DNA via a tyrosyl phosphate bond. This covalently linked protein has the same reduced molecular weight as purified calf thymus DNA topoisomerase II. The possibility that topoisomerase II-mediated DNA breaks may be responsible for cytotoxicity has also been investigated using a number of m-AMSA-related acridines. The level of topoisomerase II-mediated DNA breaks in vitro strongly correlates with the level of protein-linked DNA breaks in cultured cells and drug-induced cytotoxicity. These results suggest that mammalian DNA topoisomerase II may be a cytotoxic target of antitumor acridines.

1 This work was supported by NIH Grants GM-27731 and CA-39662.

2 American Cancer Society postdoctoral fellow. Present address: Department of Pharmacology and Therapeutics, University of Florida, Gainesville, FL 32610.

3 To whom requests for reprints should be addressed, at Department of Biological Chemistry, Johns Hopkins Medical School, 725 N. Wolfe St., Baltimore, MD 21205.

Received 9/ 9/85. Revised 1/ 7/86. Accepted 1/ 7/86.




This article has been cited by other articles:


Home page
JCOHome page
L. N. Harris, G. Broadwater, M. Abu-Khalaf, D. Cowan, A. D. Thor, D. Budman, C. T. Cirrincione, D. A. Berry, E. P. Winer, C. A. Hudis, et al.
Topoisomerase II{alpha} Amplification Does Not Predict Benefit From Dose-Intense Cyclophosphamide, Doxorubicin, and Fluorouracil Therapy in HER2-Amplified Early Breast Cancer: Results of CALGB 8541/150013
J. Clin. Oncol., July 20, 2009; 27(21): 3430 - 3436.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
A. Ganguly, B. Das, A. Roy, N. Sen, S. B. Dasgupta, S. Mukhopadhayay, and H. K. Majumder
Betulinic Acid, a Catalytic Inhibitor of Topoisomerase I, Inhibits Reactive Oxygen Species Mediated Apoptotic Topoisomerase I DNA Cleavable Complex Formation in Prostate Cancer Cells but Does Not Affect the Process of Cell Death
Cancer Res., December 15, 2007; 67(24): 11848 - 11858.
[Abstract] [Full Text] [PDF]


Home page
Arch Otolaryngol Head Neck SurgHome page
S. J. Wang, K. Peyrollier, and L. Y. Bourguignon
The Influence of Hyaluronan-CD44 Interaction on Topoisomerase II Activity and Etoposide Cytotoxicity in Head and Neck Cancer
Arch Otolaryngol Head Neck Surg, March 1, 2007; 133(3): 281 - 288.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
S.-H. Juang, C.-C. Lung, P.-C. Hsu, K.-S. Hsu, Y.-C. Li, P.-C. Hong, H.-S. Shiah, C.-C. Kuo, C.-W. Huang, Y.-C. Wang, et al.
D-501036, a novel selenophene-based triheterocycle derivative, exhibits potent in vitro and in vivo antitumoral activity which involves DNA damage and ataxia telangiectasia-mutated nuclear protein kinase activation
Mol. Cancer Ther., January 1, 2007; 6(1): 193 - 202.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
C.-C. Kuo, J.-F. Liu, and J.-Y. Chang
DNA Repair Enzyme, O6-Methylguanine DNA Methyltransferase, Modulates Cytotoxicity of Camptothecin-Derived Topoisomerase I Inhibitors
J. Pharmacol. Exp. Ther., February 1, 2006; 316(2): 946 - 954.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
J. E. Karp, A. Passaniti, I. Gojo, S. Kaufmann, K. Bible, T. S. Garimella, J. Greer, J. Briel, B. D. Smith, S. D. Gore, et al.
Phase I and Pharmacokinetic Study of Flavopiridol followed by 1-{beta}-D-Arabinofuranosylcytosine and Mitoxantrone in Relapsed and Refractory Adult Acute Leukemias
Clin. Cancer Res., December 1, 2005; 11(23): 8403 - 8412.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
J.-Y. Chang, J.-F. Liu, S.-H. Juang, T.-W. Liu, and L.-T. Chen
Novel Mutation of Topoisomerase I in Rendering Cells Resistant to Camptothecin
Cancer Res., July 1, 2002; 62(13): 3716 - 3721.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
L. N. Harris, L. Yang, V. Liotcheva, S. Pauli, J. D. Iglehart, O. M. Colvin, and T. S. Hsieh
Induction of Topoisomerase II Activity after ErbB2 Activation Is Associated with a Differential Response to Breast Cancer Chemotherapy
Clin. Cancer Res., June 1, 2001; 7(6): 1497 - 1504.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
P. S. Kingma and N. Osheroff
Topoisomerase II-mediated DNA Cleavage and Religation in the Absence of Base Pairing. ABASIC LESIONS AS A TOOL TO DISSECT ENZYME MECHANISM
J. Biol. Chem., July 17, 1998; 273(29): 17999 - 18002.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M. Olivier, B.-J. Romero-Gallo, C. Matte, J. Blanchette, B. I. Posner, M. J. Tremblay, and R. Faure
Modulation of Interferon-gamma -induced Macrophage Activation by Phosphotyrosine Phosphatases Inhibition. EFFECT ON MURINE LEISHMANIASIS PROGRESSION
J. Biol. Chem., May 29, 1998; 273(22): 13944 - 13949.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
M. Binaschi, G. Capranico, L. Dal Bo, and F. Zunino
Relationship between Lethal Effects and Topoisomerase II-Mediated Double-Stranded DNA Breaks Produced by Anthracyclines with Different Sequence Specificity
Mol. Pharmacol., June 1, 1997; 51(6): 1053 - 1059.
[Abstract] [Full Text]


Home page
Mol. Pharmacol.Home page
N. Fujii, Y. Yamashita, T. Mizukami, and H. Nakano
Correlation between the Formation of Cleavable Complex with Topoisomerase I and Growth-Inhibitory Activity for Saintopin-Type Antibiotics
Mol. Pharmacol., February 1, 1997; 51(2): 269 - 276.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1986 by the American Association for Cancer Research.